West Lafayette-based Cook Biotech Inc. is partnering with AcuityBio Inc. in Massachusetts to continue work on a lung cancer product. The companies say they will collaborate on the advancement of AcuityBio’s ABC103, which will feature proprietary technology from Cook Biotech.
ABC103 will use Cook Biotech’s extracellular matrix technology, which AcuityBio Chief Executive Officer Jay Schwartz says brings exciting possibilities to the partnership.
"We believe that the solidification of our relationship with Cook Biotech will allow us to build on our two companies’ strengths, such as AcuityBio’s drug-delivery expertise and Cook Biotech’s unique medical device technology platform, know how, and market experience," said Schwartz. "Working together will speed development of our combined AcuityBio-Cook Biotech lead product for lung cancer, ABC103, ultimately providing a solution to a critical unmet medical need and the betterment of patient outcomes."
Financial terms of the agreement are not being disclosed. Cook Biotech is a subsidiary of Bloomington-based Cook Medical Holdings and is located in the Purdue Research Park.